Zymeworks Presents Safety And Anti-Tumor Activity Data From The Ongoing Phase I Study Of ZW25 At ASCO Annual Meeting (ASCO 2017) Post author:Sam Post published:June 4, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Patient Dies in Cellectis' Groundbreaking CAR-T Trial, Forcing a Halt to Trials September 4, 2017 Kindred Bio To Announce Fourth Quarter And Year-End 2016 Financial Results February 20, 2017 TG Therapeutics Announces Updated Results From the Ongoing Phase II Study of Ublituximab in Patie… February 1, 2018
TG Therapeutics Announces Updated Results From the Ongoing Phase II Study of Ublituximab in Patie… February 1, 2018